Abstract:Introduction: The major challenge to effective oncolytic viral-mediated cancer therapy is the lack of tumor-specific targeting. Myeloid derived suppressor cells (MDSCs) are immature myeloid cells induced by tumor factors which have been shown to migrate to tumors. Better understanding of the kinetics of MDSC migration may enable the use of MDSCs as delivery vectors for tumor-specific therapies. Vesicular Stomatitis Virus (VSV) is an oncolytic rhabdovirus which requires high doses for effective peripherally administered cancer therapy. These doses carry a likelihood of neurotoxic effects in humans. We hypothesize that MDSCs can improve delivery and decrease side effects of VSV therapy. Methods: Ly6C+ monocytic MDSCs were isolated from tumor-bearing BALB/c mice. Cells were stained with Feridex and PKH26 dye and adoptively transferred into BALB/c mice with intrahepatic MCA26 colon cancer. Mice received daily MRI and were sacrificed for FACS, relaxometry, or mass spectrometry. Intrahepatic MCA26 tumor-breaing mice were treated with injection of 5x106 MDSCs cultured with VSV or VSV(M3) virus (MOI:300), with or without α-VSV-G ab and compared for survival to mice receiving PBS, MDSCs alone, free virus, and Ly6c- cells cultured with VSV. Mice were sacrificed and organs harvested for histology and TCID50. Results: We demonstrate via MRI that MDSCs migrate to tumors in an adoptive transfer model of murine hepatic metastases of colon cancer. MDSC levels peak intratumorally 72 hrs after transfer and are identified peripherally and perivasciularly. Intratumoral MDSC levels are elevated compared to spleen (38±2%Injected Dose (%ID) vs 13±0.6%ID, 72hrs, p<0.001), and liver (0.5±1%ID, p<0.001) via mass spectrometry and relaxometry. This is confirmed by FACS, which shows a 7-fold increase of MDSC signaling in the tumor compared to background (p=0.001). We then employ MDSCs as a delivery vehicle for VSV. VSV-infected MDSCs significantly prolong survival in mice with hepatic colon cancer over systemic administration of VSV alone (29.8 days vs 24 days; p<0.0002). Furthermore, the improvement of VSV binding efficiency on MDSCs leads to significantly improved survival when VSV is conjugated to MDSCs using α-VSV-G ab (52.9 days vs 24.9 days; p<0.0001) demonstrating 26% overall survival and no significant toxicity. We confirm increased viral delivery to tumors and decreased delivery to other tissues through histology and TCID50, indicating an improved therapeutic index for VSV therapy when administered via MDSCs. Conclusions: This study demonstrates a proof-of-principle for MDSCs preferentially targeting therapeutics to metastatic tumors. in the future we anticipate that this technique may be applied to a variety of targeted tumor therapies.

MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

[Advances in Measles Virus for Cancer Therapy].

Single‐Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR‐122 Function in Hepatocellular Carcinoma Cells by using “Smart” Mesoporous Silica Nanoparticles

Screening of candidate genes associated with high titer production of oncolytic measles virus based on systems biology approach

Mitophagy Enhances Oncolytic Measles Virus Replication by Mitigating Ddx58/Rig-I-Like Receptor Signaling

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors

miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses

Efficient Mutagenesis of Marek’s Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

A Novel Role for Myeloid Derived Suppressor Cells in Tumor-specific Therapeutic Targeting

Measles Virus as an Oncolytic Immunotherapy

Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models

Enhancing oncolytic virotherapy by exosome-mediated microRNA reprograming of the tumour microenvironment.

Forskolin Enhances Antitumor Effect of Oncolytic Measles Virus by Promoting Rab27a Dependent Vesicular Transport System

Optimization of microRNA Target Sequence Arrangement in AAV Vectors Dramatically Enhances Specificity and Efficiency of Transgene Expression in Cortical Microglia

The Application of Multiple Mirna Response Elements Enables Oncolytic Adenoviruses to Possess Specificity to Glioma Cells.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy

Identification and characterization of host miRNAs that target the mouse mammary tumour virus (MMTV) genome

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity